Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
J&J MedTech
Location
Language
English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
English
Français
US
English
UK
English
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Our culture of inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our history
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Inclusion
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Menu
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Our culture of inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our history
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Inclusion
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Show Search
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
2,132 Results
Date
All Dates (2132)
Past 30 days (14)
2023 (139)
2022 (124)
2021 (184)
2020 (109)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (2132)
Corporate (147)
Financial (303)
Innovative Medicine (963)
Leadership (20)
Medical technologies (293)
Research (41)
2,132 results
Filters
Date
All Dates (2132)
Past 30 days (14)
2023 (139)
2022 (124)
2021 (184)
2020 (109)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (2132)
Corporate (147)
Financial (303)
Innovative Medicine (963)
Leadership (20)
Medical technologies (293)
Research (41)
Sort By:
Newest
Newest
Relevance
Oldest
May 15, 2025
Shockwave Medical Highlights Commitment to Transform Treatment of Cardiovascular Disease at EuroPCR 2025
23 abstracts, including three late-breaking data presentations, to underscore the company’s scientific leadership in IVL and Reducer technology and the strength of its portfolio
Read more
May 14, 2025
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Read more
May 13, 2025
New Breast Implant Closes the Reconstruction Gap for 1 in 7 Women After Breast Cancer Surgery
MENTOR™ MemoryGel™ Enhance Breast Implants are the first and only implant designed to meet the reconstruction needs of women with larger breast sizes who have undergone a mastectomy Patients who previously lacked access to proportionately sized implants for reconstruction are now afforded the same clinical benefits that have long been available to others
Read more
May 9, 2025
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill
Read more
May 8, 2025
Johnson & Johnson expands efforts to champion the nursing workforce globally
New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges
Read more
May 5, 2025
Johnson & Johnson’s New “Oncology Care Index” Highlights the Growing Divide Between Cancer Innovation and Implementation in Clinical Practice
73% of surveyed HCPs say there’s a gap between the availability of new, cutting-edge treatments and their successful implementation in clinical practice; 3 in 4 oncologists find the pace of new treatment development overwhelming Insights will boost Johnson & Johnson’s strong approach to supporting oncologists with the resources and opportunities needed to enhance patient care and stay informed on emerging treatments.
Read more
May 5, 2025
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn’s disease
Read more
May 5, 2025
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92
Read more
Innovative Medicine
April 30, 2025
Johnson & Johnson receives FDA approval for IMAAVYTM (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study and ongoing open-label extension (OLE)
Read more
April 28, 2025
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
Read more
Load More